Multivariable analysis showed that higher baseline IgG [OR = 1.95, 95% CI 1.05-3.63, <i>P</i> = 0.035] and anti-β2GPI IgG levels [OR = 1.06, 95% CI 1.01-1.12, <i>P</i> = 0.048] were independently associated with SRI-4 response at week 24.<h4>Conclusion</h4>Telitacicept may represent a safe and effective therapeutic option for patients with aPL-positive SLE, potentially exerting its therapeutic effects by influencing B-cell subsets, particularly DN B cells and plasmablasts. This evidence concerns the gene FASLG and systemic lupus erythematosus.